Different tumors have different types of immune responses. We would like to better understand the drivers of this differential response so that we can best treat these tumors.
What are the goals of this project?
The goal of this project is to investigate determinants of the tumor-associated immune response in pediatric lower grade glioma.
What is the impact of this project?
Our overall goal is to identify determinants of the immune microenvironment in glioma so that therapeutic strategies targeting the relevant pathways can be prioritized for the patients who are most likely to benefit.
Why the CBTN request is important to this project?
Using data from CBTN, we can investigate whether these mRNA and protein-level differences can be appreciated in a larger, unbiased data set when comparing specific molecular tumor subsets. Preliminary analyses of gene expression data in PedCBioPortal demonstrate a robust difference in the factors we are interested in.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas
Joseph Shieh and Schuyler Tong, Bioinformaticians
Joanna Phillips, MD, PhD
I am an Associate Professor in the UCSF Departments of Neurological Surgery and Pathology, Director of the UCSF Brain Tumor Research Center Tissue Biorepository and Histology Core, Co-Director of the UCSF Neuropathology BTRC Biomarkers Laboratory, Co-Director of the UCSF Brain Tumor SPORE Biorepo
UCSF Benioff Children's Hospital
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Low-Grade astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still suffer from the eff